Connecting Claims and Outcomes: Applying Accessibility Criteria to Alternate Assessments

The study’s purpose was to evaluate how accessibility is forwarded through technical test specification and how specifications are influenced by policy guidance. Although universal design (UD) is frequently identified as a guiding principle in test development, Johnson, Trantham, and Usher-Tate (2019) found many assessment programs neither realize these promises, nor ensure the necessary steps for optimal accessibility. We reviewed assessment development approaches and features in light of UD principles by conducting a qualitative review of relationships between UD elements and Peer Review Critical Elements (2018), and the relationships between UD elements and “Criteria for Procuring Evaluating High-Quality Assessments (CCSSO, 2014) using expert judgment (Patton, 2002). Results illustrated where raters identified UD elements within policy guidance and showed a concentration of references to UD in test development processes, consistent with findings from previous studies (Davidson, 2019). Results suggest the limited definition of fairness and a view that accessibility is only a consideration at the item level may contribute to the lack of connection to these UD elements in Peer Review guidance

Approximate square-root-time relaxation in glass-forming liquids

We present data for the dielectric relaxation of 43 glass-forming organic liquids, showing that the primary (alpha) relaxation is often close to square-root-time relaxation. The better an inverse power-law description of the high-frequency loss applies, the more accurately is square-root-time relaxation obeyed. These findings suggest that square-root-time relaxation is generic to the alpha process, once a common view, but since long believed to be incorrect. Only liquids with very large dielectric losses deviate from this picture by having consistently narrower loss peaks. As a further challenge to the prevailing opinion, we find that liquids with accurate square-root-time relaxation cover a wide range of fragilities

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins.

Possible involvement of complement (C) systems in the pathogenesis of traumatic brain injury (TBI) was investigated by quantifying Cproteins in plasma astrocyte-derived exosomes (ADEs) of subjects with sports-related TBI (sTBI) and TBI in military veterans (mtTBI) without cognitive impairment. All sTBI subjects (n&nbsp;=&nbsp;24) had mild injuries, whereas eight of the mtTBI subjects had moderate, and 17 had mild injuries. Plasma levels of ADEs were decreased after acute sTBI and returned to normal within months. Cprotein levels in ADEs were from 12- to 35-fold higher than the corresponding levels in neuron-derived exosomes. CD81 exosome marker-normalized ADE levels of classical pathway C4b, alternative pathway factor D and Bb, lectin pathway mannose-binding lectin (MBL), and shared neurotoxic effectors C3b and C5b-9 terminal C complex were significantly higher and those of C regulatory proteins CR1 and CD59 were lower in the first week of acute sTBI (n&nbsp;=&nbsp;12) than in controls (n&nbsp;=&nbsp;12). Most C abnormalities were no longer detected in chronic sTBI at 3-12 months after acute sTBI, except for elevated levels of factor D, Bb, and MBL. In contrast, significant elevations of ADE levels of C4b, factor D, Bb, MBL, C3b and C5b-9 terminal C complex, and depressions of CR1 and CD59 relative to those of controls were observed after 1-4 years in early chronic mtTBI (n&nbsp;=&nbsp;10) and persisted for decades except for normalization of Bb, MBL, and CD59 in late chronic mtTBI (n&nbsp;=&nbsp;15). Complement inhibitors may be useful therapeutically in acute TBI and post-concussion syndrome